The Big Bet on NeoProbe

Earlier this month, Neoprobe (AMEX: NEOP  ) completed the sale of its handheld gamma radiation detector business to Devicor Medical Products. The company pocketed $30 million up-front with the potential for another $20 million in royalties if Devicor can hit certain sales milestones. If focusing on drugs can work for the big boys -- Bristol-Myers Squibb (NYSE: BMY  ) and Pfizer (NYSE: PFE  ) in particular -- why not a small company as well?

The sale transforms Neoprobe into a pure-play drug developer, although it's sticking with its radiation roots. Neoprobe's lead product, Lymphoseek, is a radioactive tracing agent that helps doctors identify lymph nodes that might contain tumor cells in patients with breast cancer and melanoma that has spread there.

The company submitted its marketing application on Aug 10, so it should hear back from the FDA in the beginning of October about whether the application was accepted. Assuming a standard 10-month review, Neoprobe get a decision in the middle of next year.

How the bet wins, how it loses
With a majority of Neoprobe's eggs in the Lymphoseek basket -- there's only one product in an earlier stage of development -- the company needs an approval to get a win. The data testing Lymphoseek looked good, but there's a question over whether Neoprobe used the right comparator in the trial. The phase 3 trials compared Lymphoseek to vital blue dye, but doctors often use a combination of vital blue dye and a sulfur colloid agent to map out the lymph nodes.

Neoprobe argues that the recent approval of Pharmalucence Sulfur Colloid Injection based solely on comparisons to vital blue dye means the FDA will do the same for Lymphoseek.

That sounds completely reasonable, but the agency isn't known for being reasonable. With a newly approved drug on the market -- albeit just a month before its application was submitted -- might the agency want a comparison to the new standard of care? Crazier things have happened.

If the FDA turns down Lymphoseek, it's clearly a loss for Neoprobe, but there's varying degrees of how much it might fall. At one extreme, anything requiring a new clinical trial would be a major blow. At the other level, a request for data it already has on hand or a minor issue with manufacturing that can be cleared up easily could be considered a win, even though it'll result in a delay getting onto the market.

Management has made its bet (sort of)
After the marketing application was filed and the sale of the detector business was complete, President and CEO Mark Pykett made a purchase of stock -- as did three of the directors.

Normally, I'd say that's an endorsement of the company that should be paid attention to; management at Biosante Pharmaceuticals (Nasdaq: BPAX  ) , Celgene (Nasdaq: CELG  ) , and Optimer Pharmaceuticals (Nasdaq: OPTR  ) all made major purchases of stock during the market downturn earlier this month.

But when you look at the size of Pykett's purchase -- less than $11,500 -- it's not much of an endorsement. And according to the SEC documents, those are the only shares he owns. Two of the directors made larger purchases that brought the value of their ownership over the $100,000 level, so at least they've got some decent skin in the game.

Place your bets (or not)
The way to make money in biotech is to find cases where investors are more worried about an approval than they should be (or less worried, if you're shorting the stock). But for Lymphoseek, it's extremely difficult to determine what the FDA's requirements for approval might be, which makes calculating the risk-reward equation very difficult.

Neoprobe might skyrocket on an approval, but investors would be better off watching from the sidelines than investing blindly. If you've got better insight into why Lymphoseek might or might not be approved, share in the comment box below.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (9) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On August 31, 2011, at 7:29 PM, Palantir777 wrote:

    fair piece for the most part.. as far as sitting on the sidelines or "investing blindly" that is where a possible bias may be inferred. a fool and his money is soon parted and anyone who invests blindly is a (motley) fool. point being the neop longs(i`m one) that i`ve met(shareholder`s meeting on 8/15/2011) are well versed relative to this company`s strategy, management`s execution relative to said strategy, results of the phase 3 Lymphoseek clinical(s), the ongoing status on RIGGS, etc...... NEWSFLASH:no blind and foolish long investing occurring with NEOP here. carry on.

  • Report this Comment On September 01, 2011, at 12:06 AM, skewbie1 wrote:

    lympho will not fail.

  • Report this Comment On September 01, 2011, at 5:26 AM, stockbuddy wrote:

    I think its worth the try for $3.30 per share.

  • Report this Comment On September 01, 2011, at 8:55 AM, camp3102 wrote:

    Well, One out of three aint bad.

    The article surely did amuse, but it was far from educating or enriching.

  • Report this Comment On September 01, 2011, at 9:59 AM, 2011james wrote:

    Do we all think that Neoprobe did the comparison test without the direction of the FDA? If so why all the pre test meetings. Neop. did what they were instructed to do. As far as the SC submission, there were no independent tests that I read about. They submitted research papers and historic documents of its use with Blue dye. I am not sure that SC can be effective on its own. Lymphoseek will get approval and hopefully they will get fast tracked to help all the patients in need.

  • Report this Comment On September 01, 2011, at 12:18 PM, skewbie1 wrote:

    seems to me there would be no need for a comparison trial to SC..the FDA has the research numbers on SC or they would not have givin it approval, simply compare the numbers to lympho.

    the advantages lympho has is it is safer, and has identified cancer.

    the question is.... can SC identify cancer as a stand alone agent ?

  • Report this Comment On September 01, 2011, at 12:46 PM, astronut666 wrote:

    What a load of hooey.....

    "Neoprobe might skyrocket on an approval, but investors would be better off watching from the sidelines than investing blindly."

    ....there's been rumors of another NEOP hit piece coming out to spread more FUD (Marty still hasn't covered his short, contrary to what many believe), and this is probably it, albeit a rather weak attempt.

    The *only* correct part of the quote above applies to any and all stocks - never invest blindly, especially based on something you read on a blog or in an opinion-type article published by MF or SA.

  • Report this Comment On September 01, 2011, at 2:07 PM, prginww wrote:

    even if it gets approval, neop is a two dollar stock, and that is the hih end.

  • Report this Comment On September 26, 2011, at 2:26 PM, maunder8 wrote:

    Neoprobe had been a victim of what many consider to have been a very fraudulent and well scripted short seller attack. The entire incident has proven that the stock market can be corrupted by even the most obvious misinformation campaign designed to frighten sheep. Neoprobe is only the first salvo as the soon to follow RIGS is projected to become a blockbuster. Lymphoseek, then RIGS, and other products are being lined up as well. It's just a matter of time. Even short seller attacks in the end will not be able to take Neoprobe down. This stock will nearly triple this year from the current $3 level.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1547153, ~/Articles/ArticleHandler.aspx, 11/25/2014 5:38:22 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement